Beremagene geperpavec-svdt
Beremagene geperpavec-svdt is used to treat certain adults and children 6 months of age or older who have dystrophic epidermolysis bullosa (an inherited disorder that causes the skin to be fragile leading to blisters, wounds, skin infections, and scarring). Beremagene geperpavec-svdt is in a class of medications called gene therapy. It works by replacing a gene that promotes wound healing by strengthening and stabilizing the skin.
🔔 How should this medicine be used?
Beremagene geperpavec-svdt comes as a gel to be applied to the skin by a healthcare professional at a clinic or at home. It is usually applied directly to wounds once a week. Treatment is continued until the wound is completely healed.
It may not be possible for your doctor to treat all of your wounds at one appointment. Your doctor will decide which wounds to treat and will probably create a wound treatment plan to prioritize your treatment based on the severity of your wounds. It is important to continue weekly treatments of each wound(s) until it is completely healed. When a wound is completely healed, your doctor will probably treat other wounds.
Avoid contact with treated wounds and wound dressings or bandages for about 24 hours after treatment with beremagene geperpavec-svdt. Do not touch or scratch treated wounds or wound dressings or bandages. If contact occurs, wash the affected area well with water.
Your doctor will tell you or a caregiver how to change your wound dressings. Wash your hands and wear protective gloves when you change wound dressings. Your doctor will tell you to dispose of your gloves and used wound dressings. Follow these instructions carefully. Ask your doctor or pharmacist if you have any questions about disposing of wound dressings.
Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.
Almost two-thirds of that $3.3 trillion cost – 64% – is paid for by American tax dollars, and that amount is growing. A study by the American Journal of Public Health predicts that taxpayers will shoulder 67.3% of the burden of healthcare costs by the year 2024, Physicians for a National Health Program
